BIOA vs MEDP
BIOA: Clinical-stage biotech targeting aging biology to develop novel small-molecule therapeutics for metabolic and cardiovascular diseases, led by brain-penetrant NLRP3 inhibitor BGE-102. MEDP: Medpace is a specialized, full-service clinical contract research organization that helps biopharmaceutical and medical device companies accelerate the development of new therapies through every phase of clinical trials.
Side-by-side fundamentals
| Metric | BIOA | MEDP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $21.94 | $528.12 | |
| Market cap as of 2026-07-23 | $975M | $15.0B | |
| P/E as of 2026-07-23 | n/a | 32.69 | |
| PEG as of 2026-07-23 | -0.51 | 2.71 | BIOA lower |
| Net margin as of 2026-07-23 | -871.8% | +17.2% | MEDP higher |
| Gross margin as of 2026-07-23 | n/a | +29.1% | |
| Operating margin as of 2026-07-23 | -985.9% | +21.0% | MEDP higher |
| ROE as of 2026-07-23 | -29.4% | +120.9% | MEDP higher |
| ROA as of 2026-07-23 | -27.3% | +24.8% | MEDP higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | MEDP lower |
| Revenue growth (YoY) as of 2026-07-23 | +91.0% | +24.2% | BIOA higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +20.1% | |
| Beta as of 2026-07-23 | 2.02 | 1.15 | |
| 1-year return as of 2026-07-22 close | +392.4% | +10.5% | BIOA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.